◀ Back to EGFR
CCND1 — EGFR
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Masuda et al., Clin Cancer Res 2001
:
Treatment with EGCG inhibited phosphorylation of the
EGFR , signal transducer and activator of transcription3 ( Stat3 ), and extracellular regulated kinase (ERK) proteins and also
inhibited basal and transforming growth factor-alpha stimulated c-fos and
cyclin D1 promoter activity
Cordero et al., J Biol Chem 2002
:
In addition, 1,25 ( OH ) ( 2 ) D ( 3 ) impaired autocrine and EGF induced nuclear translocation of activated
EGFR and, consequently, its binding to AT-rich DNA sequences and transcriptional
activation of the
cyclin D1 promoter
Civenni et al., EMBO Rep 2003
:
Wnt1 and Wnt5a
induce cyclin D1 expression through
ErbB1 transactivation in HC11 mammary epithelial cells ... Importantly, Wnt transactivated
ErbB1 was
responsible for MAPK activation and the increased levels of
cyclin D1 present in the Wnt expressing HC11 cells
Lebeau et al., Breast Cancer Res Treat 2003
(Breast Neoplasms...) :
We propose that
cyclin D1 could be indirectly
induced by
ErbB signalling through p21
Petty et al., Clin Cancer Res 2004
(Gastrointestinal Neoplasms...) :
Epidermal growth factor receptor tyrosine kinase inhibition
represses cyclin D1 in aerodigestive tract cancers
Rougier et al., Semin Oncol 2007
(Carcinoma, Hepatocellular...) :
Possible future therapeutic strategies include
epidermal growth factor receptor inhibitors, antivascular endothelial growth factor therapies,
cyclin D inhibitors , and HMG-CoA reductase inhibitors
Sasaki et al., Clin Lung Cancer 2007
(Adenocarcinoma...) :
Epidermal growth factor receptor (EGFR) stimulation markedly
increases cyclin D1 protein expression
Lee et al., American journal of physiology. Renal physiology 2008
:
Consequently, the inhibition of Ca ( 2+ ), PKC,
EGFR , p44/42 MAPKs, or NF-kappaB
blocked the BSA induced increases in
cyclin D1 , cyclin dependent kinase (CDK)4, cyclin E, or CDK2 and restored the BSA induced inhibition of p21 ( WAF/Cip1 ) and p27 ( Kip1 ) expression
Ren et al., Clin Cancer Res 2008
(Sarcoma) :
EGFR blockade inhibited these effects and also
caused increased apoptosis, a p53 independent G ( 0 ) -G ( 1 ) cell cycle arrest, and decreased
cyclin D1 expression
Fox et al., Mol Endocrinol 2008
(Breast Neoplasms) :
EGFR and c-Src kinase activities were also
required for E2-induced
cyclin D1 and c-myc mRNA
Lee et al., Molecular cancer 2010
(Mouth Neoplasms) :
TOP-FLASH and FOP-FLASH reporter assays demonstrated that the
EGFR signal regulates beta-catenin transcriptional activity and
mediates cyclin D1 expression
Dragnev et al., Cancer prevention research (Philadelphia, Pa.) 2011
(Carcinoma, Non-Small-Cell Lung...) :
The
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ( TKI ) erlotinib
represses cyclin D1 via different mechanisms
Xie et al., Clin Cancer Res 2011
(Disease Models, Animal...) :
EGFR activation increased ES cell proliferation, motility, and invasion and
induced cyclin D1 , matrix metalloproteinase (MMP) 2, and MMP9 expression